Apr 17, 2023 / 01:30PM GMT
Gil Blum - Needham & Company, LLC - Analyst
Good morning, everyone. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today Adaptimmune's management team. And as a reminder, any viewers who are watching through our conference portal are able to submit questions via the ask-a-question box below the video feed window.
And with that, Adrian, please go ahead.
Adrian Rawcliffe - Adaptimmune Therapeutics plc - CEO
Thanks, Gil. Delighted to be able to introduce you all to Adaptimmune. If I can get the next slide, which is our disclaimer, which you can read on the website and move through to the subsequent slide. 3. Adaptimmune is a engineered T-cell therapy company with a particular focus on solid tumors, which puts us as differentiated with the majority of the currently marketed cell therapies in the oncology space. Specifically, our platform enable us to engineer the T-cell receptor, which is critical for enabling our engineered T cells to attack a range of solid tumors both with small
Adaptimmune Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers